We report a 66-year-old man with chronic hepatitis caused by hepatitis type C virus of genotype-1b and high-viral-load combined with cryoglobulinemia and advanced diabetic nephropathy in whom we successfully achieved viral removal and eradication by DFPP (VRAD). The dose of PEG-interferon was reduced to 70 mg/week due to thrombocytopenia. Rivavirin was discontinued at day 21 due to anemia. Even with treatment of PEG-interferon alone, the condition was judged to be sustained viral remission at the end of the observation. This is a successful report of VRAD in a combined case of diabetic and HCV-related cryoglobulinnephropathy with nephrotic syndrome. The therapeutic effect of IFN seemed to be efficiently enhanced by concomitant DFPP (VRAD therapy).
Introduction
The frequency of sustained viral remission (SVR) by treatment with peginterferon (PEG-INF) and ribavirin (RVB), which are standard treatments for genotype 1b and high-viral-load chronic hepatitis due to hepatitis C virus (HCV), is about 50%. In Japan, 70% of patients with chronic hepatitis C show genotype 1b and a high viral load, and the effectiveness of treatment is limited (1, 2). Therefore, Sakai et al. (3, 4) reported, on the basis of the pattern of the virus, that the therapeutic effect of interferon (INF) may be enhanced by the elimination of HCV from the blood by apheresis, and Yamashita et al. (5) reported that the virological response is accelerated by double filtration plasmapheresis (DFPP) combined with INF/RBV compared with conventional PEG-INF/RBV therapy. Moreover, in 2007, Fujiwara et al. (6) confirmed a higher SVR rate with DFPP and PEG-INF/RBV combination therapy compared with conventional therapy by a multi-center collaborative study. On the basis of these reports, we performed virus removal and eradication by DFPP (VRAD) in a patient with genotype 1b and high-viral-load hepatitis C virus infection accompanied by refractory nephrotic syndrome due to cryoglobulin and type 2 diabetic nephropathy. Although the administration of RBV was discontinued 21 days after the beginning of therapy due to adverse effects, SVR could be achieved by a reduced dose of PEG-INF alone. We report here the successful case of VRAD in diabetic and cryoglobulin nephropathy with nephrotic syndrome.
brothers. At the age of 56, the patient was diagnosed with diabetes mellitus and hepatitis C, and began to be treated by a local physician. At the age of 59, a diagnosis of diabetic retinopathy was made, but the history of blood sugar control was unknown. At 64, he consulted our department due to malaise and edema, and was admitted for close evaluation due to a nephrotic state, and a diagnosis of diabetic and HCV-related cryoglobulin-nephropathy ( Fig. 1) was made by renal biopsy [Clinical stage 3A in Japanese diabetic nephropathy criteria; urinary protein level = 3-4 g/day, serum creatinine level (SCr) = 0.65 mg/dL, creatinine clearance (Ccr) = 80-90 mL/ming]. Cryoglobulin was positive, and the involvement of chronic hepatitis C in the progression of nephropathy was suspected, but the patient refused interferon therapy and consequently, was observed under conservative treatment. Thereafter, the patient received oral antihyperglycemic and antihypertensive medications as an outpatient, blood sugar control became inadequate (HbA1c about 8%), insulin self-injection (pre-mixed insulin) was initiated at the age of 65 years, and the HbA1c level was controlled at about 5-6%. However, blood sugar control gradually exacerbated, and increases in urinary protein and SCr were observed (urinary protein: 5-6 g/day, SCr: 0.9 mg/dL).
Since the involvement of chronic hepatitis C in the progression of diabetic nephropathy was suspected, the patient consented to virus elimination therapy and was admitted.
Physical findings on admission were: height, 156 cm; body weight, 55.1 kg; BMI, 22.6; blood pressure, 160/88 mmHg; heart rate, 64 bpm; body temperature, 35.9 ; anemia of the palpebral conjunctiva, no jaundice of the ocular conjunctiva, no thyroid swelling, no abnormality of respiratory or heart sounds, no abnormality of the abdomen, pitting edema without purpura or livedo reticularis in the crural region, normal position sensitivity of the lower limbs, and shortened vibration sensibility. Table 1 shows the findings on admission. The maximum urinary protein level was 9 g/day, and the Ccr was 59 mL/ ming. Blood tests indicated anemia, but the platelet count and coagulation-fibrinolytic system were normal. The serum potassium level and SCr were elevated, and hypoalbuminemia and an increase in type IV collagen were also noted. HCV was genotype 1b, and the viral level was high at 6.2 Log IU/mL. Concerning the immune system, IgG was increased, and cryoglobulin was positive. The funduscopic finding on admission was Fukuda A2, and the nerve conduction velocity was slowed in the peroneal and posterior tibial nerve, being consistent with diabetic retinopathy and neuropathy. Upper gastrointestinal endoscopy and abdominal ultrasonography showed no finding suggestive of liver cirrhosis. The CTR was 50% on chest X-ray examination, and abdominal CT showed no abnormality. Fig. 2 presents the clinical course. Since this patient showed reduced renal function and anemia, the administration of PEG-INF and RBV was started respectively at 135 μg/week and half of the usual dose (400 mg/day). DFPP was performed 5 times within 2 weeks, and blood access was obtained by inserting a double lumen catheter into the right internal jugular vein. The primary membrane was Plasmaflo OP-05W (Asahi Kasei Kuraray Medical Co., Ltd., Tokyo), and the secondary membrane was Cascadeflo (Asahi Kasei Kuraray Medical Co., Ltd.). Since cryoglobulin (molecular weight, 200 Kd) was positive in the present case, Cascadeflo EC-20W (albumin sieving coefficient is 0.62. albumin loss was 45.6 g at one therapy) was used to remove IgG only at the first time. Then, an albumin preparation (200 mL of 25% albumin) was used to compensate for the loss of albumin, 50 g in this case. Cascadeflo EC-50W (albumin sieving coefficient is 0.92) was employed from the second time on. Throughout of treatment, the volume of one treatment was 50 mL/kg (3,000 mL/one therapy), the blood flow was 80 mL/ming, and the separated plasma flow was 20 mL/min. The fibrinogen level immediately after each execution of DFPP was about 150 mg/dL, and no problematic adverse event occurred during DFPP. After the beginning of VRAD therapy, a decrease in the platelet count due to PEG-INF was noted, and its dose was reduced to 70 μg/week from the second injection at 7 days after the beginning of its administration. Exacerbation of anemia was also noted, and the administration of RBV was discontinued 21 days after its initiation. The viral level decreased by more than 2 Log IU/mL at 8 days after the initiation of VRAD therapy, and, as it decreased to 1.2 Log IU/mL after 7 weeks, an early virological response (EVR) was achieved. The virus thereafter remained negative, was also negative at the end of therapy (24 weeks after its initiation), and the condition was judged to be SVR until the end of observation (72 weeks after the initiation of VRAD). Cryoglobulin became alternately positive and negative, and the urinary protein level remained 6-7 g/g·Cr, showing only a slight decrease, but the renal function was stable during PEG-IFN therapy.
Discussion
In the present patient, VRAD therapy was performed for HCV complicated by type 2 diabetic nephropathy, the administration of RBV was discontinued due to an adverse effect, and the treatment was continued with PEG-INF alone, but SVR could be achieved. Regarding the relationship between chronic hepatitis C and type 2 diabetes, HCV infection can be an independent risk factor of type 2 diabetes regardless of the presence or absence of liver cirrhosis (7, 8) . Soma et al. (9) also reported that the progression of type 2 diabetic nephropathy is accelerated by the complication of sustained HCV infection. As for the present case, the findings of renal biopsy performed in 2007 including those on electron microscopy did not contradict those of diabetic nephropathy combined with HCV related cryoglobulinnephropathy. Then, we determined that the treatment should be started early to avoid losing an opportunity to prevent the progression of diabetic nephropathy. SVR is achieved in about 50% of patients with refractory chronic hepatitis C on standard treatment at that time, i.e., PEG-INF/RBV, and the effectiveness of treatment is still unsatisfactory (10, 11) . Presently, therefore, prediction of the effectiveness of treatment of chronic hepatitis C before its initiation is considered extremely important, and many predictive factors of the effect of treatment have been reported. Among them, gene mutations and polymorphisms in the virus and host have been suggested to be factors that markedly affect the sensitivity to INF (12) (13) (14) (15) (16) (17) (18) . Particularly, it has been considered difficult to achieve SVR in a patient showing the progres- Figure 2 . clinical course. DFPP was performed 5 times within 2 weeks. Since this patient showed reduced renal function and anemia, the administration of PEG-INF and RBV was started at 135 μg/ week and half of the usual dose (400 mg/day), respectively. After the beginning of VRAD therapy, the dose of PEG-INF was reduced to 70 μg/week at day 7 due to thrombocytopenia. RBV was discontinued 21 days after its initiation. The viral level decreased to 1.2 Log IU/mL after 7 weeks, an early virological response was achieved. The virus thereafter remained negative, and the condition was judged to be SVR until the end of the observation. sion of anemia due to marked proteinuria and mild renal dysfunction due to diabetic nephropathy, in whom the therapeutic efficiency is expected to be reduced due to reductions in the dose of PEG-INF and RBV, such as in the current patient. Since Fujiwara et al. (6) reported in 2007 that an earlier virological response and a higher SVR rate could be obtained by VRAD therapy than by conventional therapy, we selected VRAD therapy, in which the conventional therapy was combined with DFPP, for our patient. Recent reports of VRAD therapy were confirmed a higher SVR in refractory cases (19, 20) . In the present case, EVR was observed in 7 weeks after the beginning of VRAD therapy, then the virological response was maintained until the end of the therapy 24 weeks after its initiation, and SVR was reached. However, renal function and proteinuria showed no drastic change by achieved SVR. The progression of diabetic nephropathy with the complication of sustained HCV infection may be reduced as reported by Soma et al. (9) . Otherwise, we should closely control the diabetic state, because the renal prognosis in this case may depend heavily on diabetic nephropathy. The effectiveness of VRAD therapy depends on the enhancement of the therapeutic effect of INF by concomitant DFPP as reported by Sakai et al. (3, 4) . The effectiveness of VRAD therapy was confirmed in our patient, who showed many factors that resist treatment such as the discontinuation of RBV. In this consideration, Namba et al. (21) also reported a case in which SVR could be achieved, and glomerulonephritis could be remitted by DFPP + PEG-INF. Their patient had many treatmentresisting factors and showed a reduced renal function due to HCV-related glomerulonephritis somewhat similar to our patient. In their patient, the therapeutic effect of IFN is considered to have been efficiently enhanced by the concomitant DFPP. Regarding the present case and the report of Namba et al. (21) , VRAD therapy may be effective in patients in whom the renal function is reduced due to HCV-related glomerulonephritis and/or other renal disorders such as diabetic nephropathy, and antiviral drugs are difficult to use. Thus, VRAD therapy is considered to be the more possible treatment to achieve SVR when antiviral drugs cannot be used for various reasons and responses cannot be expected by IFN therapy alone.
Conclusion
SVR was achieved in a genotype-1b and high-viral-load HCV positive patient combined with type 2 diabetic nephropathy and cryoglobulinemia by PEG-INF therapy alone, this is likely due to the fact that the therapeutic effect of IFN was efficiently enhanced by concomitant DFPP (VRAD therapy).
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